@article {38973,
	title = {Allosteric modulation of AMPA receptors counteracts Tau-related excitotoxic synaptic signaling and memory deficits in stress- and Aβ-evoked hippocampal pathology},
	journal = {Mol Psychiatry},
	volume = {26},
	number = {10},
	year = {2021},
	note = {10.1038/s41380-020-0794-5},
	month = {Oct},
	pages = {5899-5911},
	edition = {20200528},
	abstract = {Despite considerable progress in the understanding of its neuropathology, Alzheimer{\textquoteright}s disease (AD) remains a complex disorder with no effective treatment that counteracts the memory deficits and the underlying synaptic malfunction triggered by the accumulation of amyloid beta (Aβ) and Tau protein. Mounting evidence supports a precipitating role for chronic environmental stress and glutamatergic excitotoxicity in AD, suggesting that targeting of glutamate receptor signaling may be a promising approach against both stress and AD pathologies. In light of the limited cognitive benefit of the direct antagonism of NMDA receptors in AD, we here focus on an alternative way to modify glutamatergic signaling through positive allosteric modulation of AMPA receptors, by the use of a PAM-AMPA compound. Using non-transgenic animal model of Aβ oligomer injection as well as the combined stress and Aβ i.c.v. infusion, we demonstrate that positive allosteric modulation of AMPA receptors by PAM-AMPA treatment reverted memory, but not mood, deficits. Furthermore, PAM-AMPA treatment reverted stress/Aβ-driven synaptic missorting of Tau and associated Fyn/GluN2B-driven excitotoxic synaptic signaling accompanied by recovery of neurotransmitter levels in the hippocampus. Our findings suggest that positive allosteric modulation of AMPA receptors restores synaptic integrity and cognitive performance in stress- and Aβ-evoked hippocampal pathology. As the prevalence of AD is increasing at an alarming rate, novel therapeutic targeting of glutamatergic signaling should be further explored against the early stages of AD synaptic malfunction with the goal of attenuating further synaptic damage before it becomes irreversible.},
	keywords = {*Alzheimer Disease/drug therapy, *Amyloid beta-Peptides/metabolism, Animals, Hippocampus/metabolism, Memory Disorders/drug therapy, Receptors, AMPA/metabolism, tau Proteins/metabolism},
	isbn = {1359-4184},
	author = {Monteiro-Fernandes, D. and Silva, J. M. and Soares-Cunha, C. and Dalla, C and Kokras, N and Arnaud, F. and Billiras, R. and Zhuravleva, V. and Waites, C. and Bretin, S. and Sousa, N. and Sotiropoulos, I}
}
